

### Publishable Summary

This deliverable reports on the current implementation of amyloid PET in main intervention trials and provides expert guidance from literature evidence and AMYPAD analysis on the most appropriate use of the technique in upcoming trials.

The use of amyloid-PET in trials has evolved over the past 10 years, from inclusion criteria to outcome measure. However, some strategies could still be taken to further improve trial design. Based on the scientific work performed in AMYPAD, the following suggestions could be provided: 1) dynamic acquisition and full quantitation when targeting intermediate amyloid burden, 2) taking the extent of amyloid pathology into account and stratify analyses based on disease stage, 3) acknowledge the presence of disease heterogeneity in terms of amyloid deposition and its association with vascular burden to further optimize patient selection and/or stratification. Together, these methodological considerations could improve power to detect a significant benefit for patients in clinical trials

For more information: [info@amypad.org](mailto:info@amypad.org)

**Acknowledgement:** This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115952. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA.



innovative  
medicines  
initiative